Pulmonary veno-occlusive disease (PVOD) is a rare, severe World Health Organisation Group 1 pulmonary arterial hypertension (PAH) subtype with poor survival. pulmonary arterial hypertension-targeted vasodilators can cause life-threatening pulmonary edema in Pulmonary veno-occlusive disease, underscoring the need for diagnostic tools to distinguish it from other pulmonary arterial hypertension subtypes
The findings of a study recently published in the Journal of Clinical Investigation, suggest that GDF15 (Growth Differentiation Factor 15), may serve as a diagnostic biomarker to distinguish pulmonary veno-occlusive disease from other pulmonary arterial hypertension subtypes. Early identification of this condition would enable appropriate treatment strategies, including earlier consideration for lung transplantation
Citation
Amit Prabhakar, Eckart M.D.D. De Bie, Jacqueline T. DesJardin, Prajakta Ghatpande, Stefan Gräf, Luke S. Howard, S. John Wort, Colin Church, David G. Kiely, Emily Sumpena, Thin Aung, Shenrae Carter, Jasleen Kukreja, Steven Hays, John R. Greenland, Jonathan P. Singer, Michael Wax, Paul J. Wolters, Marc A. Simon, Mark Toshner, Giorgio Lagna, and Akiko Hata, J Clin Invest. 2025. https://doi.org/10.1172/JCI199159.
Read more at this link on the Journal of Clinical Investigation